<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03957031</url>
  </required_header>
  <id_info>
    <org_study_id>LEGACY-1</org_study_id>
    <nct_id>NCT03957031</nct_id>
  </id_info>
  <brief_title>Gastric Cancer Risk Factors Associated With EU and CELAC Populations</brief_title>
  <acronym>LEGACY-1</acronym>
  <official_title>Gastric Cancer Risk Factors Associated With EU and CELAC Populations</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fundación para la Investigación del Hospital Clínico de Valencia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Instituto Nacional de Cancerologia de Mexico</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>VU University Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Pontificia Universidad Catolica de Chile</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Vall d'Hebron Institute of Oncology</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>INSTITUTO ALEXANDER FLEMING</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hospital Central del IPS</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>INSTITUTO DE PATOLOGIA E IMUNOLOGIA MOLECULAR DA UNIVERSIDADE DO PORTO PCUP</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Fundación para la Investigación del Hospital Clínico de Valencia</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study uses a case‐control design that examines the differences in types of exposures
      between cases defined with a pathological confirmation of GC diagnosis, and controls, defined
      as patients to whom a gastroscopy was indicated and confirmed absent of GC i
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      GC is associated to several known risk factors. Epidemiological and molecular features of GCs
      can vary widely. The reasons behind these differences are multiple and complex and may
      include genetic susceptibility, strains of the bacterium Helicobacter pylori (H. pylori),
      Epstein Barr virus infection, dietary factors and others. These factors can influence GC
      outcomes. There is little knowledge regarding how these risk factors are associated with GC
      in CELAC and EU populations.

      The primary objectives of this study are to:

        1. Identify risk factors associated with GC in the CELAC and EU populations participating
           in this study including Argentina, Spain, Mexico, Netherlands, Chile, Portugal and
           Paraguay.

        2. Identify clinical, demographic, and epidemiological differences among the populations
           participating in this study
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 31, 2019</start_date>
  <completion_date type="Anticipated">December 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Exposure to a variety of potential sources of GC risk factors</measure>
    <time_frame>3 years</time_frame>
    <description>The ratio of the odds of exposure vs. odds of no exposure to a variety of potential sources of GC risk factors in cases vs. controls.</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">1600</enrollment>
  <condition>Cancer, Gastric</condition>
  <arm_group>
    <arm_group_label>Cases</arm_group_label>
    <description>Patients with a pathological confirmation of GC diagnosis</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <description>Patients with confirmed absent of GC</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        -  Subjects &gt;18 years old, with GC diagnosis.

          -  Subjects &gt;18 years old to whom a gastroscopy was indicated and confirmed absent of GC
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Cases

          -  Inclusion criteria

               -  Subjects ≥18 years old.

               -  GC diagnosis (including gastroesophageal junction cancer) from IPATIMUP, INCAN,
                  VUMC, PUC, VHIO, IAF, INCLIVA and GENPAT centres, in the last six months before
                  his/her inclusion in the study.

               -  Has given and signed the IC to participate in this study.

          -  Exclusion criteria:

               -  Patients diagnosed with GC (including gastroesophageal junction cancer) from
                  other centres/ countries not participating in this proposal.

               -  Patients with suspected with GC diagnosis but not confirmed by the pathological
                  report.

        Controls

          -  Inclusion criteria

               -  Subjects ≥18 years old.

               -  Subjects to whom a gastroscopy was indicated in its medical care and confirmed
                  absent of GC in the same centres will be matched in age (+/- 10 years), gender
                  and pertaining from the same region of the GC case. Thus, to match our GC cases
                  same number of controls is expected to be recruited.

               -  Has given and signed the IC to participate in this study.

          -  Exclusion criteria:

               -  Subjects from a different geographic area from the cases.

               -  Patients with high suspicion of GC (including gastroesophageal junction cancer)
                  or previous personal history known of document chronic gastritis diagnosed by
                  endoscopy and confirmed by histology.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Andrés Cervantes, MD</last_name>
    <phone>+ 34 961973543</phone>
    <email>andres.cervantes@uv.es</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Tania Fleitas, MD</last_name>
    <phone>+ 34 961973543</phone>
    <email>tfleitask@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Instituto Alexander Fleming</name>
      <address>
        <city>Buenos Aires</city>
        <zip>C1426NZ</zip>
        <country>Argentina</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Juan Manuel O'Connor, MD PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Pontificia Universidad Católica de Chile</name>
      <address>
        <city>Santiago</city>
        <zip>8331150</zip>
        <country>Chile</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marcelo Garrido, MD PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Instituto Nacional de Cancerología</name>
      <address>
        <city>Mexico City</city>
        <zip>01480</zip>
        <country>Mexico</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Erika Ruiz, MD PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>VU Medical Centre</name>
      <address>
        <city>Amsterdam</city>
        <zip>1081</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sarah Derks, MD PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>GenPat</name>
      <address>
        <city>Asunción</city>
        <country>Paraguay</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carmelo Caballero, MD PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institute of Pathology and Immunology of University of Porto</name>
      <address>
        <city>Porto</city>
        <zip>4200 135</zip>
        <country>Portugal</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Fátima Carneiro, MD PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Fundació Privada Institut d'Investigació Oncològica de Vall-Hebron (VHIO)</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maria Alsina, MD PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Clínico Universitario de Valencia</name>
      <address>
        <city>Valencia</city>
        <zip>46010</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andres Cervantes, Professor</last_name>
    </contact>
    <contact_backup>
      <last_name>Tania Fleitas, PhD</last_name>
    </contact_backup>
  </location>
  <location_countries>
    <country>Argentina</country>
    <country>Chile</country>
    <country>Mexico</country>
    <country>Netherlands</country>
    <country>Paraguay</country>
    <country>Portugal</country>
    <country>Spain</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>May 17, 2019</study_first_submitted>
  <study_first_submitted_qc>May 20, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">May 21, 2019</study_first_posted>
  <last_update_submitted>July 21, 2020</last_update_submitted>
  <last_update_submitted_qc>July 21, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 22, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Gastric Cancer</keyword>
  <keyword>Personalized medicine</keyword>
  <keyword>Oncology</keyword>
  <keyword>Solid tumor</keyword>
  <keyword>Primary Intervention</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stomach Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

